亚临床甲状腺功能低下症:一种新的心力衰竭预测因子,在HFrEF患者中改善了喷射分数
Haiqing Zhou1, Qi Wang1, Zhiquan Liu1
1Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
Internal and emergency medicine
|December 17, 2024
概括
亚临床甲状腺功能低下症 (SCH) 与心力衰竭改善排气分数 (HFimpEF) 的可能性较低,与心力衰竭减少排气分数 (HFrEF) 的患者有关. 这表明甲状腺功能会影响HFrEF患者的心脏恢复.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 内部医学 内部医学
背景情况:
- 心力衰竭 (HF) 与改善的射出分数 (HFimpEF) 越来越多地被认为是其有利的预后.
- 甲状腺功能障碍,特别是亚临床甲状腺功能障碍 (SCH) 在HF患者心脏功能恢复中的作用仍在研究中.
研究的目的:
- 为了调查亚临床甲状腺功能低下症 (SCH) 与心力衰竭与改善排泄率 (HFimpEF) 在最初被诊断为心力衰竭与减少排泄率 (HFrEF) 的患者的发展之间的关联.
主要方法:
- 对916名HFrEF患者的回顾性分析,根据基线甲状腺功能分为甲状腺和SCH组.
- 患者被分为HFimpEF (随访LVEF>40%和绝对增加≥10%) 或持久的HFrEF.
- 使用后勤回归模型来评估SCH对HFimpEF的影响.
主要成果:
- 在916名患者中,396名 (43.2%) 进展为HFimpEF.
- 与持久性HFrEF组 (14.4%) 相比,HFimpEF组的SCH患病率明显较低 (9.3%).
- 在多变量调整后,SCH被确定为一个独立的预测因子,与37.8%降低HFimpEF (OR:0.622,P=0.038) 进展的几率相关.
结论:
- 甲状腺功能显著影响HFrEF患者心脏功能改善.
- 亚临床甲状腺功能低下症独立地与在HFrEF患者中实现改善射出分数的可能性较低有关.
- 这些发现强调了在心力衰竭的管理和预后中考虑甲状腺状况的重要性.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:20Mitral Regurgitation I: Introduction
1
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1
01:22Heart Failure Drugs: Diuretics
339
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
01:22Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382